Brief: FDA Issuance Of A Priority Review Voucher To The Sponsor Of A Rare Pediatric Disease Product Application- Federal Register Website
01/04/2026 14:15
April 1 (Reuters) - Rocket Pharmaceuticals Inc RCKT.O: FDA: ISSUANCE OF A PRIORITY REVIEW VOUCHER TO THE SPONSOR OF A RARE PEDIATRIC DISEASE PRODUCT APPLICATION- FEDERAL REGISTER WEBSITE FDA: DETERMINED THAT KRESLADI MEETS THE CRITERIA FOR A PRIORITY REVIEW VOUCHER- FEDERAL REGISTER WEBSITE Source text: [ID:] Further company coverage: RCKT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rocket Pharmaceuticals
See all newsRocket Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Rocket Pharmaceuticals, Inc. expected to post a loss of 42 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Rocket Pharmaceuticals posts Q2 profit helped by PRV sale
Brief: Rocket Pharmaceuticals Q2 EPS USD 1.08